Kabra Drugs Ltd (KABRADG) is currently trading at 15.82 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Kabra Drugs Limited manufactures ether derivatives (diethyl ether, solvent ether, ethyl chloride spray) from its Indore facility and markets a broad pharmaceutical and disinfectant product portfolio of over 500 SKUs across India; the company recently expanded into disinfectants and claims sole domestic manufacture of certain antimicrobial hand wash gel formulations while being a registered supplier to the Ministry of Defence. Kabra Drugs reported a material financial turnaround in FY26 with standalone revenue from operations of Rs. 9,274.00 lakhs and total income of Rs. 9,323.27 lakhs, delivering profit before tax of Rs. 572.07 lakhs and net profit of Rs. 495.98 lakhs; this reverses the prior-year loss and reflects a restart of commercial activity after earlier working-capital constraints. Despite reported profitability, Kabra’s operating cash flow was negative Rs. 947.43 lakhs in FY26 driven by an extraordinary increase in trade receivables to Rs. 7,077.60 lakhs and trade payables of Rs. 5,483.48 lakhs; cash and cash equivalents declined to Rs. 1,058.23 lakhs, signaling acute collection risk and short-term liquidity pressure despite improved earnings. Reported results were affected by accounting and tax transitions: the company adopted Ind AS 116 for leases (recognizing additional depreciation and finance costs and reversing rent), restated comparative figures, and elected the concessional tax regime under Section 115BAA, which increased current tax expense in FY26 relative to prior periods. Operationally management emphasizes cost-reduction measures to restore operations after working-capital scarcity while modest capex during the year and focus on disinfectant product lines indicate cautious scaling; management signals efforts to improve collections and better monetise its 500+ product catalogue rather than pursuing aggressive expansion this fiscal.

Over the past 52 weeks, Kabra Drugs Ltd has traded between a low of ₹15.50 and a high of ₹35.52. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Kabra Drugs Ltd has a market capitalization of approximately 38.29. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Kabra Drugs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 5.04 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 38.29 Cr, Kabra Drugs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Kabra Drugs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Kabra Drugs Ltd is 5.04. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.